FcγRIIB specific antibodies and methods of use thereof

Details FcγRIIB specific antibodies and methods of use thereof FcγRIIB specific antibodies and methods of use thereof

2003-08-14

2008-09-16

Haddad, Maher M. (Department: 1644)

Chemistry: natural resins or derivatives; peptides or proteins;

Proteins, i.e., more than 100 amino acid residues

Blood proteins or globulins, e.g., proteoglycans, platelet...

C530S387300, C530S388100, C530S388150, C530S391100, C435S326000, C424S130100, C424S133100, C424S135100, C424S136100, C424S140100, C424S142100, C424S143100

Reexamination Certificate

active

07425619

ABSTRACT:
The present invention relates to antibodies or fragments thereof that specifically bind FcγRIIB, particularly human FcγRIIB, with greater affinity than said antibodies or fragments thereof bind FcγRIIA, particularly human FcγRIIA. The invention provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing efficacy of a vaccine composition by administering the antibodies of the invention.

REFERENCES:
patent: 4179337 (1979-12-01), Davis et al.
patent: 5648260 (1997-07-01), Winter et al.
patent: 5711944 (1998-01-01), Gilbert et al.
patent: 5837243 (1998-11-01), Deo et al.
patent: 5888533 (1999-03-01), Dunn
patent: 5945115 (1999-08-01), Dunn et al.
patent: 6019968 (2000-02-01), Platz et al.
patent: 6132764 (2000-10-01), Li et al.
patent: 6194551 (2001-02-01), Idusogie et al.
patent: 6218149 (2001-04-01), Morrison et al.
patent: 6339069 (2002-01-01), Meers et al.
patent: 6420149 (2002-07-01), Fukuda et al.
patent: 6472511 (2002-10-01), Leung et al.
patent: 6528624 (2003-03-01), Idusogie et al.
patent: 6737056 (2004-05-01), Presta
patent: 2001/0036459 (2001-11-01), Ravetch
patent: 2002/0028486 (2002-03-01), Morrison et al.
patent: 2003/0115614 (2003-06-01), Kanda et al.
patent: 2004/0002587 (2004-01-01), Watkins et al.
patent: 2004/0185045 (2004-09-01), Koenig et al.
patent: 2004/0191244 (2004-09-01), Presta
patent: 2005/0037000 (2005-02-01), Stavenhagen et al.
patent: 2005/0215767 (2005-09-01), Koenig et al.
patent: 2005/0260213 (2005-11-01), Koenig et al.
patent: 2006/0013810 (2006-01-01), Johnson et al.
patent: 2006/0073142 (2006-04-01), Chan et al.
patent: 2006/0177439 (2006-08-01), Koenig et al.
patent: 2007/0253948 (2007-11-01), Chan et al.
patent: 0 332 865 (1989-09-01), None
patent: 0 629 703 (1994-12-01), None
patent: 0 359 096 (1997-11-01), None
patent: 0 953 639 (1999-11-01), None
patent: 1 006 183 (2000-06-01), None
patent: 0 343 950 (2000-10-01), None
patent: WO 94/18330 (1994-08-01), None
patent: WO 99/19362 (1999-04-01), None
patent: WO 99/41285 (1999-08-01), None
patent: WO 99/58572 (1999-11-01), None
patent: WO 00/42072 (2000-07-01), None
patent: WO 01/79299 (2001-10-01), None
patent: WO 03/035835 (2003-05-01), None
patent: WO 03/066095 (2003-08-01), None
patent: WO 2004/016750 (2004-02-01), None
patent: WO 2005/110474 (2005-11-01), None
patent: WO 2005/115452 (2005-12-01), None
patent: WO 2006/066078 (2006-06-01), None
patent: PCT/US07/72151 (2007-06-01), None
Ott et al. J. Allergy Clin. Immunol. 2001. 108:S95-S98).
Reff et al. Critical Review i Oncology/Hematology. 2000. 40:25-35.
Merriam-Webster's Collegiate Dictionary. Published by Merriam-Webster, Inc. 1997 10th Edition, p. 382.
Oxford Dictionary of Biochemistry and Moleculra Biology. Revised Edition published by Oxford University Press. 2000. p. 205.
Abra et al., The next generation of liposome delivery systems: recent experience with tumor-targeted, sterically-stabilized immunoliposomes and active-loading gradients. J Liposome Res. Feb.-May, 2002;12(1-2):1-3.
Bendas G, Immunoliposomes: a promising approach to targeting cancer therapy. BioDrugs. 2001;15(4):215-24.
Billadeau et al., ITAMs versus ITIMs: striking a balance during cell regulation, J Clin Invest. Jan. 2002;109(2):161-8.
Bolland and Ravetch., Inhibitory pathways triggered by ITIM-containing receptors. Adv Immunol. 1999;72:149-177.
Bolland et al., Genetic modifiers of systemic lupus erythematosus in FcγRIIB(-/-) mice. J Exp Med. May 6, 2002;195(9):1167-74.
Boruchov et al., Expression and modulation of the inhibitory Fcγ receptor, FcγRIIB (CD32b), on human dendritic cells (DCs). Laboratory of Cellular Immunobiology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, NY, NY 10021.
Brauweiler et al., Partially distinct molecular mechanisms mediate inhibitory FcγRIIB signaling in resting and activated B cells. J Immunol. 2001;167:204-211.
Brown EJ., In vitro assays of phagocytic function of human peripheral blood leukocytes: receptor modulation and signal transduction. Methods Cell Biol. 1994;45:147-164.
Budde et al., Specificity of CD32 mAB for FcγRIIa, FcγRIIb1, and FcγRIIb2 expressed in transfected mouse B cells and BHK-21 cells. Leukocyte Typing V: White cell differentiation antigens. 1995;828-832 (Schlossman, Boumsell, Gilks, Harlan, Kishomoto, eds.).
Callanan et al., The IgG Fc Receptor, FcγRIIB is a target for deregulation by chromosomal translocation in malignant lymphoma. PNAS. Jan. 2000;97(1):309-314.
Cameron et al., Differentiation of the human monocyte cell line, U937, with dibutyryl cyclicAMP induces the expression of the inhibitory Fc receptor, FcγRIIb. Immunol Lett. Oct. 1, 2002;83(3):171-9.
Camilleri-Broët et al., FcγRIIB is differentially expressed during B cell maturation and in B-cell lymphomas. Br J Haematol. 2004;124(1):55-62.
Cassard et al., Modulation of tumor growth by inhibitory Fcγ receptor expressed by human melanoma cells. The J Clin Invest. Nov. 2002;110(10):1549-1557.
Chappel et al., Identification of the FCγ receptor class I binding site in human IgG through the use of recombinant IgG1/IgG2 hybrid and point-mutated antibodies. Proc. Natl. Acad. Sci. USA. Oct. 1991;88(20):9036-9040.
Clynes et al., Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 2000;6(4):443-6.
Damle et al., B-cell chronic lymphocytic leukemia cells express a surface membrane phenotype of activated, antigen-experienced B lymphocytes. Blood Jun. 1, 2002;99(11):4087-4093.
Davies et al., Expression of GnTIII in a recombinant anti-CD20 CHO production cell line: Expression of antibodies with altered glycoforms leads to an increase in ADCC through higher affinity for FCγRIII. Biotechnol Bioeng. Aug. 20, 2001;74(4):288-94.
Daëron et al., The Same Tyrosine Based Inhibition Motif, in the Intracytoplasmic Domain of FcγRIIB, regulates negatively BCR, TCR- and FcR dependent cell activation. Immunity. Nov. 1995;3: 635-646.
Ding et al., Inhibition of the function of the FcγRIIB by a monoclonal antibody to thymic shared antigen-1, a Ly-6 family antigen. Immunology. Sep. 2001;104(1):28-36.
Eppstein et al., Biological activity of liposome-encapsulated murine interferon γ is mediated by a cell membrane receptor. Proc Natl Acad Sci U S A. Jan. 1985;82(11):3688-92.
Fanger et al., Production and use of anti-FcR bispecific antibodies. Immunomethods. Feb. 1994;4(1):72-81.
Farag, et al., FcγRIIIa and FcγRIIIa polymorphisms do not predict response to Rituximab in B-cell chronic lymphocytic leukemia. Blood. Oct. 16, 2003 (15 pp.).
Fidler, I. J., Macrophages and metastasis—a biological approach to cancer therapy. Cancer Res. Oct. 1985;45(10):4714-26.
Gerber et al., Stimulatory and inhibitory signals originating from the macrophage Fcγ receptors. Microbes Infect. Feb. 2001;3(2):131-9.
Holmes et al., Alleles of the Ly-17 alloantigen define polymorphisms of the murine IgG Fc receptor. Proc Natl Acad Sci USA. Nov. 1985;82(22):7706-10.
Hwang et al., Hepatic uptake and degradation of unilamellar sphingomyelin/cholesterol liposomes: a kinetic study. Proc Natl Acad Sci U S A. Jul. 1980;77(7):4030-4.
Isaacs et al., Therapy with monoclonal antibodies. II. The contribution of Fcγ receptor binding and the influence of CH1 and CH3 domains on in vivo effector function. The Journal of Immunology. 1998;161:3862-3869.
Jefferis et al., Recognition sites on human IgG for Fcγ receptors: the role of glycosylation. Immunol Lett. Jan. 1995;44(2-3):111-7.
Kagari et al., Essential Role of Fcγ Receptors in anti-type II collagen antibody induced arthritis. J. Immunol. Apr. 2003;170:4318-24.
Lifely et al., Glycosylation and biological activity of CAMPATH-1H expressed in different cell lines and grown under different culture conditions. Glycobiology. Dec. 1995;5(8):813-22.
Lin et al., Colony-stimulating factor 1 promote

Affiliated with

Also associated with

Rating

FcγRIIB specific antibodies and methods of use thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with FcγRIIB specific antibodies and methods of use thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and FcγRIIB specific antibodies and methods of use thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3988612